ğŸ”¬ HIGH-PRIORITY CORRECTIONS & ENHANCEMENTS
1. Biological Labels Are Too Generic

    Terms like â€œPopulation Aâ€ or â€œPopulation Bâ€ are not meaningful for clinical or research use.

âœ… Replace with specific cell types, e.g.:

- Sensitive Tumor Cells (ALK+)
- Resistant Tumor Clones
- CD8+ T Cells
- NK Cells
- Myeloid-Derived Suppressor Cells (optional)

2. Simulation Output Lacks Clinical Units

    The Y-axis is in arbitrary units.

âœ… Recommendation:

    Show population in relative % or estimated cell count (e.g. 1e6 cells)

    Allow user to toggle between log scale and linear

3. Lack of Time Control & Realistic Dosing

    Time axis is unlabeled (days? weeks?).

    No dose control or drug half-life behavior.

âœ… Add:

- Time unit toggle (days/weeks/months)
- Drug administration schedule (continuous, pulsed, adaptive)
- Half-life input (tied to drug decay curve)

4. Immune System Is Oversimplified

    Appears as one undifferentiated immune response.

    Doesn't reflect immune suppression by tumor or feedback inhibition.

âœ… Suggested Model Expansion:

    Add variable for tumor-mediated suppression (IL-10/TGF-Î² analog)

    Add parameter: immune exhaustion over time

    Plot immune activation vs suppression balance

5. No Resistance Evolution Yet

    Resistance is static â€” tumor populations are pre-defined as resistant or not.

âœ… Add Evolutionary Game Theory Layer:

# Simple version:
if treatment_pressure > threshold:
    mutation_rate += f(environmental_pressure)
    resistant_cells += mutated_cells

# Output:
â€œ% resistant cells increasing under drug exposureâ€

6. Graphs Need Event Markers

    Treatment start, stop, or transitions aren't labeled on the graph.

âœ… Add event markers to plot, e.g.:

- Vertical line on Day 20: â€œDrug ONâ€
- Shaded area: â€œImmunotherapy phaseâ€

7. No Clinical Scenario Templates

Currently, the user has to enter abstract numbers.

âœ… Add drop-down presets, such as:

- Scenario 1: ALK+ NSCLC on Brigatinib
- Scenario 2: EGFR-mutant NSCLC on Osimertinib
- Scenario 3: High PD-L1 NSCLC on Pembrolizumab

Each with pre-filled growth/resistance/immune parameters.
8. Missing Real-World Biomarker Integration

âœ… Add:

- ctDNA output curve (reflecting tumor burden)
- IL-6 / CRP curve (reflecting inflammation)
- PD-L1 score estimate (adjusts immune effect)

9. User Interface Suggestions

    Add tooltips on each parameter: e.g. â€œDrug Efficacy: reduction in tumor growth per time unitâ€

    Allow real-time adjustment: sliders that auto-update simulation

